Agenus Inc. [NASDAQ: AGEN] stock went on a downward path that fall over -3.85% on Wednesday, amounting to a one-week price decrease of less than -15.49%. The company report on September 10, 2021 that New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks.
Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines.
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections announced the launch of SaponiQx, a subsidiary of Agenus, dedicated to driving innovation in novel adjuvant discovery and vaccine design, and its partnership with Ginkgo Bioworks, Inc. (“Ginkgo”), the leading horizontal platform for cell programming. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), is enabling customers across industries to improve products and manufacturing processes, and to increase efficiency and sustainability, by making biology easier to engineer.
Over the last 12 months, AGEN stock rose by 7.29%. The one-year Agenus Inc. stock forecast points to a potential upside of 43.37. The average equity rating for AGEN stock is currently 1.30, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.26 billion, with 222.91 million shares outstanding and 203.28 million shares in the current float. Compared to the average trading volume of 3.51M shares, AGEN stock reached a trading volume of 8113386 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Agenus Inc. [AGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $9.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 19, 2019. The new note on the price target was released on April 22, 2019, representing the official price target for Agenus Inc. stock. Previously, the target price had yet another drop from $10 to $5, while H.C. Wainwright kept a Neutral rating on AGEN stock.
The Average True Range (ATR) for Agenus Inc. is set at 0.32, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 18.40.
AGEN Stock Performance Analysis:
Agenus Inc. [AGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.49. With this latest performance, AGEN shares dropped by -9.05% in over the last four-week period, additionally plugging by 66.41% over the last 6 months – not to mention a rise of 7.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 37.38, with the RSI for the last a single of trading hit 29.65, and the three-weeks RSI is set at 42.42 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 5.79, while it was recorded at 6.07 for the last single week of trading, and 4.25 for the last 200 days.
Insight into Agenus Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Agenus Inc. [AGEN] shares currently have an operating margin of -340.25. Agenus Inc.’s Net Margin is presently recorded at -434.14.
Reflecting on the efficiency of the workforce at the company, Agenus Inc. [AGEN] managed to generate an average of -$543,170 per employee. Receivables Turnover for the company is 35.49 with a Total Asset Turnover recorded at a value of 0.27.Agenus Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 0.60.
Agenus Inc. [AGEN] Insider Position Details
There are presently around $618 million, or 49.80% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: BLACKROCK INC. with ownership of 16,145,203, which is approximately 13.284% of the company’s market cap and around 0.60% of the total institutional ownership; VANGUARD GROUP INC, holding 13,903,405 shares of the stock with an approximate value of $74.73 million in AGEN stocks shares; and RTW INVESTMENTS, LP, currently with $61.48 million in AGEN stock with ownership of nearly -16.985% of the company’s market capitalization.
Positions in Agenus Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 88 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 14,512,156 shares. Additionally, 53 investors decreased positions by around 15,517,873 shares, while 25 investors held positions by with 84,945,751 shares. The mentioned changes placed institutional holdings at 114,975,780 shares, according to the latest SEC report filing. AGEN stock had 24 new institutional investments in for a total of 3,124,092 shares, while 19 institutional investors sold positions of 891,155 shares during the same period.